Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX) Short Interest Update

Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 483 shares, an increase of ∞ from the August 15th total of 0 shares. Based on an average daily volume of 1,006 shares, the days-to-cover ratio is presently 0.5 days.

Leverage Shares 2X Long FIX Daily ETF Price Performance

BATS FIXX traded up $0.04 during trading hours on Tuesday, reaching $12.07. The company’s stock had a trading volume of 3,460 shares, compared to its average volume of 2,609. Leverage Shares 2X Long FIX Daily ETF has a 1 year low of $11.21 and a 1 year high of $14.30.

Insider Activity

In other Leverage Shares 2X Long FIX Daily ETF news, CEO Jodie Pope Morrison sold 9,845 shares of Leverage Shares 2X Long FIX Daily ETF stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total transaction of $163,033.20. Following the completion of the transaction, the chief executive officer owned 343,259 shares in the company, valued at approximately $5,684,369.04. The trade was a 2.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shelia M. Violette sold 2,798 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $46,334.88. Following the completion of the sale, the insider directly owned 127,771 shares in the company, valued at approximately $2,115,887.76. This represents a 2.14% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 16,615 shares of company stock valued at $275,144 over the last quarter.

Homology Medicines, Inc was a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare diseases. The company sought to use its proprietary human-derived adeno-associated virus vectors, known as AAVHSCs, to deliver gene therapies in vivo and address the underlying causes of inherited disorders.

Its development programs included HMI-103, an investigational gene therapy for phenylketonuria, as well as earlier programs targeting other rare diseases.